Teva believes its generic version of Mylan's EpiPen will capture 25 percent of the US market by the end of the year, as reported Yahoo!Finance Tuesday.
Analysts previously estimated that the generic drug could boost Teva's annual revenue for $250 million and earnings per share by $0.04 to $0.06.
According to CEO Kare Schultz, Teva has introduced the adult version of the therapy, while the paediatric version will be unveiled later this year.
Meanwhile, many pharmacy chains and distributors have to receive supplies of Teva's generic version of EpiPen.
The news comes as Mylan's product has been in short supply due to manufacturing issues at a Pfizer facility that produces the auto-injection device.
Teva's generic version of EpiPen was approved by the FDA last August after several years of delay.
To read more NewsPoints articles, click here.